Related Experiment Videos
DPC-423 Bristol-Myers Squibb
1University of Naples Federico II, Department of Neuroscience, Italy. mtaglial@unina.it
Current Opinion in Investigational Drugs (London, England : 2000)
|May 22, 2002
Abstract:
DPC-423 is a biphenylamine-containing amide which is under development by Bristol-Myers Squibb (formerly DuPont Pharmaceuticals) as a Factor Xa inhibitor for the potential treatment of thrombotic disorders [372092]. As of August 2000, DPC-423 was in phase I trials [380880]. DPC-423 was discovered as a result of SAR modifications of DuPont's SN-429, including replacement of the benzamidine moiety with a less basic benzylamine [398701]. Its 2-aminomethylphenyl analog DPC-602 is also under investigation for thrombotic disorders [402714].